Toward the close of a call with analysts on Wednesday, CEO Mary Szela of Cambridge drugmaker Aegerion Pharmaceuticals called the company’s plans to merge with Canadian drugmaker QLT “an opportunity for a fresh start.”
In some ways the news, announced this week, has already helped, resulting in a stock surge of as much as 67 percent before settling back down this morning as of 11 a.m. to $1.54, up 18 percent from Tuesday’s close. But that’s clearly small comfort for Aegerion’s (Nasdaq: AEGR) major investors, including Scopia Capital, which owns a 19.3 percent stake in the company.
